Taysha Gene Therapies, Inc. (TSHA) Cash Flow Statement
Taysha Gene Therapies, Inc. (TSHA) generated -$132.2M of operating cash flow over the twelve months to 2026-06-30, spent $381000 on capital expenditure and had free cash flow of -$132.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TSHATaysha Gene Therapies, Inc.Follow TSHA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Operating cash flow | -88.4 | -73.0 | -81.2 | -93.1 | -132.2 | |
| Capital expenditure | 20.6 | 3.9 | 0.4 | 0.7 | -0.4 | |
| Free cash flow | -109.0 | -76.9 | -81.6 | -93.8 | -132.6 | |
| Stock-based compensation | 18.0 | 7.9 | 13.1 | 13.3 | — |
USD millions · SEC XBRL
Taysha Gene Therapies, Inc. — questions
- What is Taysha Gene Therapies, Inc.'s operating cash flow?
- -$132.2M over the twelve months to 2026-06-30.
- How much does Taysha Gene Therapies, Inc. spend on capital expenditure?
- $381000 over the twelve months to 2026-06-30.
- What is Taysha Gene Therapies, Inc.'s free cash flow?
- -$132.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Taysha Gene Therapies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.